Analysts See $-0.02 EPS for Enzo Biochem, Inc. (ENZ)

December 8, 2017 - By reb123z

 Analysts See $ 0.02 EPS for Enzo Biochem, Inc. (ENZ)
Investors sentiment increased to 1.59 in 2017 Q2. Its up 0.30, from 1.29 in 2017Q1. It is positive, as 12 investors sold Enzo Biochem, Inc. shares while 27 reduced holdings. 28 funds opened positions while 34 raised stakes. 25.22 million shares or 2.12% more from 24.70 million shares in 2017Q1 were reported.
Focused Wealth Mngmt Incorporated stated it has 110 shares. Hillsdale Mgmt Inc has 0.03% invested in Enzo Biochem, Inc. (NYSE:ENZ). Gilder Gagnon Howe & Com Ltd Liability Corporation has 0.16% invested in Enzo Biochem, Inc. (NYSE:ENZ). Ny State Common Retirement Fund has 0% invested in Enzo Biochem, Inc. (NYSE:ENZ). 23,895 are owned by Neuberger Berman Grp Ltd Co. Tfs Cap Lc stated it has 0.12% of its portfolio in Enzo Biochem, Inc. (NYSE:ENZ). Price T Rowe Assoc Md stated it has 0% in Enzo Biochem, Inc. (NYSE:ENZ). Loomis Sayles And Company Limited Partnership accumulated 0% or 417 shares. 31,831 were accumulated by Metropolitan Life Insur. Goldman Sachs Gp Inc holds 0% or 206,234 shares. Abner Herrman And Brock Ltd Liability Corp invested in 100,000 shares or 0.21% of the stock. Zacks Mgmt invested in 0% or 15,675 shares. Us Fincl Bank De invested in 745 shares or 0% of the stock. Mckinley Capital Management Delaware has 455,042 shares for 0.19% of their portfolio. The Georgia-based Invesco Limited has invested 0% in Enzo Biochem, Inc. (NYSE:ENZ).

Since June 13, 2017, it had 0 insider purchases, and 1 sale for $160,054 activity.

Analysts expect Enzo Biochem, Inc. (NYSE:ENZ) to report $-0.02 EPS on December, 14.They anticipate $0.01 EPS change or 33.33 % from last quarter’s $-0.03 EPS. The stock increased 2.59% or $0.24 during the last trading session, reaching $9.51. About 170,018 shares traded. Enzo Biochem, Inc. (NYSE:ENZ) has risen 44.32% since December 8, 2016 and is uptrending. It has outperformed by 27.62% the S&P500.

Enzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company has market cap of $446.26 million. The firm operates in three divisions: Clinical Labs, Life Sciences, and Therapeutics. It currently has negative earnings. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition.

More notable recent Enzo Biochem, Inc. (NYSE:ENZ) news were published by: Seekingalpha.com which released: “Enzo Biochem (ENZ) on Q3 2017 Results – Earnings Call Transcript” on June 09, 2017, also Businesswire.com with their article: “Enzo Biochem Reports Improved First Quarter Results” published on December 07, 2017, Businesswire.com published: “Enzo Biochem Reports Delaware Court Ruling” on June 29, 2017. More interesting news about Enzo Biochem, Inc. (NYSE:ENZ) were released by: Seekingalpha.com and their article: “Enzo Biochem’s (ENZ) on Q2 2017 Results – Earnings Call Transcript” published on March 14, 2017 as well as Businesswire.com‘s news article titled: “Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results …” with publication date: December 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.